Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Average PT from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $16.75.

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th.

Institutional Trading of Amicus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Old West Investment Management LLC lifted its holdings in shares of Amicus Therapeutics by 617.2% in the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after purchasing an additional 292,976 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Amicus Therapeutics by 46.3% in the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,484 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Amicus Therapeutics by 163.8% in the third quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company’s stock valued at $1,429,000 after purchasing an additional 83,081 shares in the last quarter. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at about $26,000. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at about $113,000.

Amicus Therapeutics Stock Up 0.1 %

Shares of NASDAQ:FOLD opened at $8.89 on Thursday. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -49.39, a PEG ratio of 1.51 and a beta of 0.69. The firm’s 50-day simple moving average is $9.40 and its 200-day simple moving average is $10.19. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics has a fifty-two week low of $8.55 and a fifty-two week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.